Administration of voriconazole in disseminated penicilliosis marneffei:a retrospective study

WEI Jin-ying; OUYANG Yan-yin; CAI Shuang-qi; LIANG Hao; CAO Cun-wei

doi:10.3969/j.issn.1673-3827.2017.02.008

Abstract：Objective The aim of this retrospective study is to evaluate the efficacy and safety of voriconazole in the treatment of Penicilliosis marneffei (PSM)patients with or without HIV infection in clinical setting.Methods The disseminated PSM patients who received intravenous voriconazole (6 mg/kg every 12 hours for the first 24 hours and then 4 mg/kg every 12 hours afterwards) as primary antifungal treatment were enrolled.The following duration of antifungal treatment varied at the discretion of investigators according to the response of the patients.Primary response was evaluated at Week 16 or at the end of treatment (EOT).Follow-up evaluations were performed at 6 months and 1 year after EOT.Results A total of seventeen patients enrolled in this study,three patients were not evaluable because the treatment discontinued prematurely.Among the remaining fourteen patients,thirteen had satisfied response to treatment,ten patients had complete response and three patients had partial response at Week 16.Only one patient was evaluated as failure.Follow-up assessments in eleven patients showed eight patients were cured and the remaining three patients relapsed at 6 months after EOT.Eight patients were assessed 1 year later,none of them relapsed.No adverse events associated to voriconazole were recorded during the treatment.Conclusion The results from our study suggest that voriconazole is an effective,well-tolerated therapeutic option for disseminated P.marneffei infection.